HalfLifeDBEvidence before certainty.

Phenibut evidence profile

The available reviews describe absorption, adverse events, dependence, and withdrawal, but the current citation set does not provide a sufficiently documented modern human concentration-time study for the former eight-hour input.

Category: gabaergic · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References4Linked studies, labels, reviews, or identity records described below

Phenibut: evidence and interpretation notes

Why HalfLifeDB does not plot Phenibut

The available reviews describe absorption, adverse events, dependence, and withdrawal, but the current citation set does not provide a sufficiently documented modern human concentration-time study for the former eight-hour input.

Phenibut has a relatively thin and uneven pharmacokinetic evidence base. Much public discussion repeats a small number of secondary sources.

The citations include a pharmacology review, a recent toxicology review, a dependence-management case review, and the compound record.

This page does not provide dependence, tapering, withdrawal, or dosing guidance.

What each source contributes

  • Lapin I. Phenibut: a tranquilizer and nootropic drug (2001). This supporting literature record adds compound-specific background and is used only within the limits of its design.
  • Phenibut: A drug with one too many buts (2024). This supporting literature record adds compound-specific background and is used only within the limits of its design.
  • Phenibut dependence and management case review (2018). This synthesis organizes the available literature and caveats and cannot replace checking the underlying study design.
  • PubChem: Phenibut. This identity record confirms names and compound identity and does not supply a human half-life.

For Phenibut, the decision to withhold a curve turns on the limits visible in Lapin I. Phenibut: a tranquilizer and nootropic drug (2001). This supporting literature record adds compound-specific background, but it is used only within the limits of its design.

What evidence would change the page

A defensible Phenibut curve would require repeated human samples and a reported estimate for Phenibut itself, rather than an inference from species, cases, related compounds, or class behavior. The current key record, Lapin I. Phenibut: a tranquilizer and nootropic drug (2001), answers a narrower question.

InterpretationCategory context and evidence limits

GABAergic substance context

GABAergic entries require extra care because sedation, impairment, tolerance, withdrawal, and combination effects can diverge from a simple parent-compound curve.

  • The chart does not estimate impairment or respiratory/CNS-depressant risk.
  • Withdrawal and tolerance are outside the half-life model.
  • Combination effects require qualified clinical or toxicology context.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

2 PubMed1 PMC0 DailyMed1 PubChem
  1. Research abstract Lapin I. Phenibut: a tranquilizer and nootropic drug (2001).
    Supporting literature record. Its role and study design should be read from the linked source before applying any numerical finding.
  2. Research abstract Phenibut: A drug with one too many buts (2024).
    Supporting literature record. Its role and study design should be read from the linked source before applying any numerical finding.
  3. Full-text research Phenibut dependence and management case review (2018).
    Synthesis or clinical background source used to frame the evidence and its limits rather than to create a new measured value.
  4. Identity record PubChem Compound Summary: Phenibut.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.